Cannabidiol (CBD) holds great promise as a treatment for many health concerns, including inflammation. For all the known benefits CBD offers, it’s unclear how well it can relieve nerve pain.
Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...